If it works for neuroendocrine cancers, then the virus could possibly be adapted for other cancers – but it would need to go through further trials to see if also worked against other types of tumour.

Until the drug is proven to work using the accepted method of clinical trials, we have to be very cautious about any claims.

All we can say is that the pre-clinical work so far looks promising.